



Human oligoclonal recombinant antivenom against the black mamba (*Dendroaspis polylepis*)

Laustsen, Andreas Hougaard; Karatt--Vellatt, Aneesh; Slavny, Peter; M. Luther, Alice; L. Olesen, Majken; W. Masters, Edward; Lomonte, Bruno; Gutiérrez, José María; McCafferty, John

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Laustsen, A. H., Karatt--Vellatt, A., Slavny, P., M. Luther, A., L. Olesen, M., W. Masters, E., Lomonte, B., Gutiérrez, J. M., & McCafferty, J. (2016). *Human oligoclonal recombinant antivenom against the black mamba (Dendroaspis polylepis)*. Poster session presented at PEGS Europe: Protein & Antibody Engineering Summit 2016, Lisbon, Portugal.

General rights


Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



IONTAS



INSTITUTO
CLODOMIRO
PICADO



Human oligoclonal recombinant antivenom against the black mamba (*Dendroaspis polylepis*)

Andreas H. Laustsen^{1,2}, Aneesh Karatt-Vellatt³; Peter Slavny³; Alice M. Luther³, Majken L. Olesen³
Edward W. Masters³, Bruno Lomonte⁴; José María Gutiérrez⁴; John McCafferty³

¹Department of Biotechnology and Biomedicine, Technical University of Denmark


²Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen

³IONTAS Ltd., Babraham Research Institute, Cambridge CB22 3AT, United Kingdom

⁴Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica


Snakebite: a neglected tropical disease

Snakebite envenoming is a major cause of death and morbidity in tropical parts of the world. Current therapies are based on animal-derived antisera that are associated with a high degree of immunogenicity, high cost, and batch-to-batch variation^{1,2}. Here, we report the results of our ongoing efforts of developing the world's first fully recombinant antivenom based on human IgGs targeting the key toxins³ from the notorious black mamba (*Dendroaspis polylepis*)⁴.





Discovery of human scFvs by phage display

Based on a combined toxicovenomics and phage display selection approach⁵, 431 human scFv binders were isolated from a phage display library against the medically relevant neurotoxins and dendrotoxins of *D. polylepis*.




Conversion of unique scFv binders to IgG

Following expression of 147 scFvs with unique V_H CDR3 regions in *E. coli* and evaluation of binding strength, the 24 most promising scFvs were selected and converted to IgG format. Of these, 20 displayed good binding after successful expression in HEK cells.



Human oligoclonal recombinant antivenoms

Currently, the binding affinities and the neutralization potential of these 20 toxin-targeting IgGs is being investigated with the aim of being able to design a cost-effective recombinant oligoclonal mixture of IgGs⁶ that can effectively neutralize the lethal effects of the synergistically-acting venom of *D. polylepis*⁷.



Oligoclonal expression of human IgGs

References

- [1] Gutiérrez JM, León G, Lomonte B, Angulo Y. In: *Inflammation & Allergy-Drug Targets* 2011; 10; p369-80.
- [2] Laustsen AH, Engmark M, Milbo C, Johannesen J, Lomonte B, Gutiérrez JM, Lohse B. *Current Pharmaceutical Design* 2016; 22.
- [3] Laustsen AH, Lohse B, Lomonte B, Engmark M, Gutiérrez JM. *Toxicon* 2015; 104; p43-45.
- [4] Laustsen AH, Lomonte B, Lohse B, Fernández J, Gutiérrez JM. *Journal of Proteomics* 2015; 119; p126-142.
- [5] Laustsen AH. *Recombinant Antivenoms*. University of Copenhagen 2016.
- [6] Laustsen AH, Johansen KH, Engmark M, Andersen MR. *Nature* 2016; 538; p41.
- [7] Laustsen AH. *Toxin Reviews* 2016; 35; p165-170.

Contact information

DTU Bioengineering
Technical University of Denmark
Søltofts Plads 223
DK-2800 Kgs. Lyngby, Denmark
ahola@bio.dtu.dk/ (+45) 2988 1134

Acknowledgements

We thank the Novo Nordisk Foundation (NNF16OC0019248), EliteForsk Rejsestipendie, Oticon Fonden, Lundbeckfonden, Fonden for Lægevidenskabens Fremme, Knud Højgaards Fond, Christian og Ottillia Brorsons rejselegat for yngre videnskabsmænd og kvinder, IONTAS Ltd., and Instituto Clodomiro Picado for financial support.